12:00 AM
 | 
Nov 06, 2006
 |  BioCentury  |  Finance

EPS watch

EPS watch

EPS watch
Biogen Idec (BIIB) was the big winner among the profitable biotechs and pharma companies that reported earnings last week. The company gained 8% on the week - about $1.2 billion - after reporting EPS and revenues that beat the consensus numbers, and raising its FY06 EPS guidance. "We had very strong performance from the core business," said CEO James Mullen. Sales of Avonex interferon beta-1a were up 19% quarter-over-quarter to $445.2 million, and Rituxan rituximab revenues from BIIB's joint business with Genentech (DNA) were up 12% to $204 million. Avonex is marketed for multiple sclerosis (MS) and Rituxan is marketed for rheumatoid arthritis (RA) and non-Hodgkin's lymphoma (NHL). (A) Results for fiscal 1Q07; Mcap in $M
Company 3Q06 EPS est 3Q06 EPS actual Outcome Growth from 3Q05 11/3 cls Wk chg % chg Mcap...

Read the full 740 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >